Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Blank

Showing results (41-50 of 89) with videos related to

Pageof 9
Sort By:
Journal of Molecular Medicine (Berlin, Germany)|January 18, 2012
High expression of GCLC is associated with malignant melanoma of low oxidative phenotype and predicts a better prognosisDimitrios Mougiakakos, Riki Okita, Takashi Ando, et al.
Oncoimmunology|March 12, 2020
Lactate dehydrogenase: a marker of diminished antitumor immunitySandra Van Wilpe, Rutger Koornstra, Martijn Den Brok, et al.
The Lancet. Oncology|July 6, 2023
Adjuvant immune checkpoint blockade revisitedSahar Barjesteh van Waalwijk van Doorn-Khosrovani, Atse Huisman, Anke Pisters-van Roy, et al.
World Journal of Urology|January 16, 2009
Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgeryAxel Bex, Astrid A M van der Veldt, Christian Blank, et al.
International Journal of Cancer|February 17, 2006
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitroChristian Blank, Juergen Kuball, Simon Voelkl, et al.
Expert Review of Dermatology|November 4, 2009
Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical interventionLuigi Strizzi, Lynne-Marie Postovit, Naira V Margaryan, et al.
International Journal of Cancer|July 1, 2011
PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic diseaseHolger Krönig, Kathrin Julia Falchner, Marcus Odendahl, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2021
Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!Michele Maio, Christian Blank, Andrea Necchi, et al.
Journal for Immunotherapy of Cancer|July 12, 2022
Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteinsTim B Fessenden, Lauren E Stopfer, Fiona Chatterjee, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 21, 2024
Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapyWei Yen Chan, Jenny H Lee, Ashleigh Stewart, et al.
Pageof 9

Showing results (41-50 of 89) with videos related to

Sort By:
Pageof 9
Journal of Molecular Medicine (Berlin, Germany)|January 18, 2012
High expression of GCLC is associated with malignant melanoma of low oxidative phenotype and predicts a better prognosisDimitrios Mougiakakos, Riki Okita, Takashi Ando, et al.
Oncoimmunology|March 12, 2020
Lactate dehydrogenase: a marker of diminished antitumor immunitySandra Van Wilpe, Rutger Koornstra, Martijn Den Brok, et al.
The Lancet. Oncology|July 6, 2023
Adjuvant immune checkpoint blockade revisitedSahar Barjesteh van Waalwijk van Doorn-Khosrovani, Atse Huisman, Anke Pisters-van Roy, et al.
World Journal of Urology|January 16, 2009
Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgeryAxel Bex, Astrid A M van der Veldt, Christian Blank, et al.
International Journal of Cancer|February 17, 2006
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitroChristian Blank, Juergen Kuball, Simon Voelkl, et al.
Expert Review of Dermatology|November 4, 2009
Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical interventionLuigi Strizzi, Lynne-Marie Postovit, Naira V Margaryan, et al.
International Journal of Cancer|July 1, 2011
PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic diseaseHolger Krönig, Kathrin Julia Falchner, Marcus Odendahl, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2021
Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!Michele Maio, Christian Blank, Andrea Necchi, et al.
Journal for Immunotherapy of Cancer|July 12, 2022
Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteinsTim B Fessenden, Lauren E Stopfer, Fiona Chatterjee, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 21, 2024
Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapyWei Yen Chan, Jenny H Lee, Ashleigh Stewart, et al.
Pageof 9